Factor VIII Concentrate: What is “High Purity”?

• References

• 1 Vermot-Desroches C, Rigal D, Blourde C, Bemaud J. Immunosuppressive property of a very high purity antihaemophilic preparation: a low molecular weight component inhibits an early step of PHA induced cell activation. Brit J Haematol 1992; 80: 370-377
• 2 Lusher JM, Salzman PM. Monoclate Study Group. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Sem in Hematol 1990; 27 (02) 1-7
• 2 Barrowcliffe TW, Watton J, Harman A, Tubbs JE, Kemball-Cook G. Potency of high purity factor VIII concentrates. The Lancet 1990; 336 (8707) 124
• 4 Fricke WA, Wong YuM. Characterization of von Willebrand Factor in Factor VIII Concentrates. Am J Hematol 1989; 31: 41-45
• 5 Weber A, Hondl F, Schoppmann A, Linnau Y. Biochemical characterization of a new, highly purified factor VIII concentrate. Poster presented at the XIV Congress of the Intemat Society on Thrombosis and Haemostasis; New York, USA: July 4-9th 1993
• 6 Gill JC. Therapy of Factor VIII Deficiency. Semin Thromb Haemost 1993; 19 (01) 1-12
• 7 Lundlam CA, Steel CM. Haemostasis: von Willebrand’s variants. The Lancet 1993; 341: 997
• 8 Furie B, Furie BC. Molecular Basis of Hemophilia. Semin Hematol 1990; 27 (03) 270-285